what compound is cagrilintide | C194H312N54O59S2 | CID 171397054 Cagrilintide (Amylin Analogue) | Synthesis

The most defensible reading is to treat each compounds own within-trial data as its evidence and to treat any cross-compound ranking as a hypothesis, not a result

Research-only note: Cagrilintide is not FDA-approved for therapeutic use

Hansen, Jakob Lerche

Apply these five checks to the popular claim retatrutide is far better than cagrilintide and it quickly reduces to: a 48-week top-dose monotherapy number for one, next to a 26-week monotherapy number for the other whose real strength is a combination with no head-to-head trial anywhere in the chain

But those are different trials with different durations and doses, and cagrilintides strongest data are as the CagriSema combination, so any ranking is a cross-trial inference rather than a proven result

The defensible, peer-reviewed statement is: standalone cagrilintide produced about 10.8% at 26 weeks at 4.5 mg in Phase 2